This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Brain cancer	Epithelial membrane protein 2 (EMP2)	<p>Patient sample and mouse studies suggest targeting EMP2 could be used to treat glioblastoma multiforme (GBM). In brain tumor samples, EMP2 expression was higher than that in healthy brain tissue, and elevated EMP2 expression correlated with poor survival. In two heterotopic xenograft mouse models of GBM, an antibody fragment or IgG targeting EMP2 led to decreased tumor growth compared with fragment or IgG controls. Next steps include testing the EMP2-targeting antibody fragment for brain penetration in intracranial mouse models of GBM.</p> <p>SciBX 7(14); doi:10.1038/scibx.2014.393 Published online April 10, 2014</p>	<p>Patented; licensed to University of California, Los Angeles start- up company Paganini Biopharma Inc.</p>	<p>Qin, Y. <i>et al. J. Biol. Chem.</i>; published online March 18, 2014; doi:10.1074/jbc.M113.543728 Contact: Madhuri Wadehra, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, Calif. e-mail: mwadehra@mednet.ucla.edu</p>